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Acute phosphate nephropathy (APhN) is a clinical pathological
entity characterized by acute and subsequent chronic renal
failure following exposure to oral sodium phosphate (OSP)
bowel purgatives. Renal biopsy findings include acute and
chronic tubular injury with prominent tubular and interstitial
calcium phosphate deposits. Risk factors for APhN include
older age, female gender, hypertension, chronic kidney
disease (CKD), and treatment with angiotensin converting
enzyme inhibitors, angiotensin receptor blockers,
and diuretics. The pathomechanism of APhN involves
hypovolemia-induced avid proximal salt and water
reabsorption, delivery of a large phosphate load to the
distal nephron, and precipitation of calcium phosphate in
the distal tubule and collecting duct. To date, 37 cases of
biopsy-proven APhN have been reported, and epidemiologic
studies have produced inconsistent results regarding
the incidence of acute kidney injury (AKI) following the
use of OSP purgatives. OSP solution was withdrawn from
the market in December of 2008, but OSP tablets, offered
by prescription only, remain available. Prevention of APhN
is best achieved by avoiding OSP in high-risk patients,
aggressive hydration before, during, and after OSP
administration, minimizing the dose of OSP, and maintaining
a minimum of a 12h interval between OSP administrations.
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Acute kidney injury (AKI) often results from drug toxicity,
several types of which cause renal injury through intratubular
crystal deposition.1 In 2003, a newly described cause of
drug-induced AKI, acute phosphate nephropathy (APhN),
was reported following the use of an oral sodium phosphate
(OSP) bowel purgative in an elderly woman.2 Renal
histopathology showed numerous tubular calcium phosphate
deposits that formed crystals of hydroxyapatite. Subsequent
observations confirmed this clinical pathological entity and
noted acute and chronic tubular injury with prominent
tubular and interstitial calcium phosphate deposits in
patients exposed to OSP purgatives.3
PHOSPHATE HOMEOSTASIS
As phosphate exposure is critical to the occurrence of APhN,
a brief review of phosphate homeostasis is undertaken. The
majority of phosphorus in humans exists as the phosphate
anion (PO4
3–) and is present in bone, with smaller amounts
present as inorganic phosphate in extracellular fluid and as
organic phosphates within cells. In blood, phosphate exists
mainly as HPO4
2– and H2PO4
1–, with relative concentrations
determined by serum pH. The average daily intake of
phosphorus in the developed world is approximately
1000mg.
Phosphate handling in the small intestine and renal
tubules is mediated by sodium-dependent phosphate co-
transporter proteins (NaPi), which are members of the SLC34
gene family.4,5 The proximal tubular brush border contains
NaPi-IIa (SLC34A1) and NaPi-IIc (SLC34A3), and their
expression is downregulated by increases in serum phosphate
or parathyroid hormone. These two factors rapidly reduce
NaPi-IIa co-transporter expression in proximal tubular apical
membrane through endosomal retrieval. NaPi-IIb (SLC34A2)
is more broadly distributed and is present in the small
intestinal brush border where levels increase in response to
hypophosphatemia and vitamin D. In contrast to renal NaPi-
IIa, intestinal NaPi-IIb expression requires days to respond to
physiological changes.
Between 60 and 80% of dietary phosphate is absorbed in
the small intestine, while net excretion occurs through
glomerular filtration minus tubular reabsorption. The
majority of phosphate is reabsorbed in the proximal tubule,
with small amounts reabsorbed in the distal tubule and
collecting duct.6,7 Hyperphosphatemia occurs in the follow-
ing settings: (1) excessive ingestion of phosphate over a short
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time period; (2) massive release of intracellular phosphate
(i.e., tumor lysis syndrome, rhabdomyolysis); (3) phosphate
ingestion in the setting of impaired gastrointestinal motility
(increased absorptive time); or (4) renal dysfunction leading
to reduced excretion.
ORAL SODIUM PHOSPHATE BOWEL PURGATIVES
Colonoscopy is critically dependent on adequate pre-
procedural bowel cleansing. In 1990, OSP solution (OSPS)
began to gain acceptance as a purgative for colonoscopy.8 The
small volume of OSPS was associated with improved patient
compliance, less discomfort, and superior colonic cleansing
compared with polyethylene glycol (PEG)-based lavage
solution. The price for a better bowel preparation was
transient hyperphosphatemia (mean increase in serum
phosphate of 4.1mg/dl) that resolved within 24 h and was
not associated with hypocalcemia.8 Subsequent studies
confirmed that OSPS was better tolerated and was associated
with improved bowel cleansing compared with PEG-based
purgatives.9–11 A meta-analysis of randomized, controlled
trials published from 1990 to 2005 found that OSPS was
more efficacious than PEG in nine studies, inferior in one
study, and equivalent in six studies.11
For many years, the commonly recommended regimen of
OSP solution (Fleet Phosphosoda; C.B. Fleet, Lynchburg, VA,
USA) consisted of two 45-ml doses taken 10–12 h apart, the
evening before and the morning of colonoscopy. Each 45-ml
dose contained 21.6 g of monobasic sodium phosphate
(NaH2PO4) and 8.1 g of dibasic sodium phosphate (Na2H-
PO4), which is equivalent to 5.8 g of elemental phosphorus.
The 5.8 g of phosphorus was diluted into a single eight ounce
glass and administered twice in a 1224 h period, far
exceeding the usual dietary intake of 1 g/day. Following
increasing reports of APhN, the more commonly recom-
mended regimen became 45ml followed by 30ml of OSP, and
requirements for hydration were increased to 36 ounces of
clear fluid with each administration. On 11 December 2008,
following continuing reports of APhN, the United States
Food and Drug Administration issued an alert stating that
over-the-counter OSP products should no longer be used for
bowel cleansing, and that the use of these products should
only occur pursuant to a prescription from a health-
care provider. (http://www.fda.gov/cder/drug/infopage/OSP_
solution/default.htm). Shortly thereafter, Fleet Phosphosoda
was voluntarily withdrawn from the US market.
Oral sodium phosphate remains available by prescription
in a tablet form under the brand names Visicol and
Osmoprep (Salix Pharmaceuticals, Morrisville, NC, USA).
These agents are given in two separate administrations
separated by 12 h. A regimen of 20 tablets of Visicol,
administered as three tablets with at least eight ounces of
clear fluid every 15min until completion, has a cumulative
sodium phosphate content that is near identical to a 45-ml
dose of OSPS. Osmoprep has largely replaced Visicol, and
current recommendations are for the second administration
to consist of 12 rather than 20 tablets. The main distinctions
between OSP solution and OSP tablets is that the latter is
tasteless, is consumed over a longer time period, mandates
greater fluid consumption, and has always been available by
prescription only.
Prior to its withdrawal, OSP was contraindicated in patients
with congestive heart failure (CHF), clinically significant
kidney failure, ascites, gastrointestinal obstruction, or active
inflammatory bowel disease. It was not recommended for use
in children under the age of 18 years, and should have been
used with caution in patients who were elderly, debilitated,
pregnant or nursing, had underlying heart disease, had
increased risk of renal impairment, and had increased risk for
or pre-existing electrolyte disturbances (www.phosphosoda.
com). For Osmoprep, the product label states that ‘considerable
caution should be advised before use’ in patients with
creatinine clearance o30ml/min, CHF, ascites, unstable
angina, gastric retention, ileus, acute bowel obstruction,
pseudo-obstruction of the bowel, severe chronic constipation,
bowel perforation, acute colitis, toxic megacolon, gastric
bypass, or hypomotility syndrome (www.osmoprep.com).
Recently, a ‘black box warning’ was added to the labels for
Visicol and Osmoprep that addresses the risk of APhN.
ACUTE PHOSPHATE NEPHROPATHY
Clinical findings
In 2004, a series of five cases of APhN was reported in
patients with a history of hypertension (HTN), a mean age of
69.2 years, and normal serum calcium levels.3 The patients
developed AKI shortly after colonoscopy preceded by bowel
cleansing with OSPS. The changes were referred to as ‘acute
nephrocalcinosis’ to emphasize the rapidity of onset com-
pared with the more commonly described forms of
nephrocalcinosis seen with hypercalcemia related to hyper-
parathyroidism, malignancy, sarcoidosis, and milk alkali
syndrome.
The same investigators subsequently reported a larger
series of patients with AKI following the use of OSP bowel
purgatives12 and adapted the term APhN1 to emphasize the
central pathogenical role of exogenous phosphate adminis-
tration. The archives of the Columbia University Renal
Pathology Laboratory from 2000–2004 were reviewed to
identify additional cases of APhN. Diagnostic criteria
included the following: (1) AKI; (2) recent exposure to
OSP bowel purgatives; (3) renal biopsy findings of acute and
chronic tubular injury with abundant calcium phosphate
deposits; (4) no evidence of hypercalcemia or conditions
associated with hypercalcemia; and (5) no other significant
pattern of renal injury. Overall, 7349 native renal biopsies
were processed over this period, of which 31 met the above-
noted criteria of acute and chronic tubular injury with
abundant calcium phosphate deposits. Twenty-one patients
met all five criteria for the diagnosis of APhN, including the
single case associated with OSP tablets which had been
previously reported.13
The cohort consisted of predominantly Caucasian women
with a mean age of 64.0 years. Sixteen patients had a history
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of HTN, including 14 who were treated with an angiotensin-
converting enzyme inhibitor (ACE-I) or angiotensin-receptor
blocker (ARB). The mean baseline serum creatinine was
88.4 mmol/l (1.0mg/dl). Patients presented with AKI and a
mean creatinine of 3.9mg/dl at a median of o1 month
following OSPS use. The mean 24-h urine protein was
256mg, and microscopic evaluation of the urine revealed
either a bland sediment or rare red or white blood cells. The
mean duration of post-colonoscopy follow-up was 16.7
months. During this time, four patients progressed to end-
stage renal disease. Sixteen of the remaining 17 patients had a
decline in serum creatinine to a mean of 2.4mg/dl. Only four
patients reached a creatinineo176.8 mmol/l (2.0mg/dl), and
no patient returned to baseline.
Additional reports of biopsy-proven APhN (Table 1) have
followed.14–24 Similar to the cases previously described,
patients appear to have taken OSPS for bowel cleansing,
possess many of the same co-morbidities, and have developed
permanent kidney damage.
Pathological findings
Renal biopsy findings in APhN primarily involve the tubules
and are dependent on the time interval between OSP use and
renal biopsy. When biopsy is performed within 3 weeks of
OSP exposure, acute tubular degenerative changes predomi-
nate and resemble findings seen in acute tubular necrosis.3,12
The acute tubular injury is accompanied by interstitial edema
and involves all tubular segments. In contrast, renal biopsies
performed more than 3 weeks following OSPS exposure
exhibit evidence of chronicity in the form of tubular atrophy
and interstitial fibrosis. As the interval from OSP exposure to
renal biopsy increases, the acute tubular degenerative changes
become less severe. This pattern of renal injury may be
described as an acute and chronic tubulointerstitial nephro-
pathy and is reminiscent of changes seen in repeat renal
biopsies from patients with non-resolving acute tubular
necrosis. Mild-to-moderate interstitial inflammation is often
seen in APhN but is not associated with significant tubulitis.
Vascular disease is a frequent finding, correlating with the
high incidence of HTN and the fact that APhN is most
commonly encountered in older patients.
Regardless of the degree of acuity or chronicity, the
hallmark of APhN is abundant tubular and less prominent
interstitial calcium phosphate deposits (Figure 1a). The
extent of tubular calcification is dependent on adequacy of
tissue sampling but in biopsies with 10 or more glomeruli,
430 calcifications are typically encountered and 4100
calcifications can be seen.3,12 The calcifications form
Table 1 | Cases of renal biopsy-proven acute phosphate nephropathy
Study
(reference) N Age/gender Baseline sCr (lmol/l) Final sCr (lmol/l) Medications/drugs Co-morbidities
Desmueles
et al.2
1 71/F 88.4 76 NA NA
Markowitz
et al.12
21 39–82/F=17, M=4 53–150.3 132–299 ESRD=4 ACE-I or ARB=14,
diuretics=4, NSAIDs=3
Hypertension=15, CKD=4,
diabetes=4
Gonlusen
et al.14
1 56/F 70 141
Manley et al.15 1 85/F NA 200 ACE-I, diuretic Hypertension
Aasebo
et al.16
1 69/F 62 114 ARB, diuretic Hypertension
Beyea et al.17 1 69/F 70 229 Hypertension
Steinman
et al.18
1 64/M 123 256 Hypertension
Connor
et al.19
1 76/F 98 271 Hypertension, CKD
Ori et al.20 5 56–73/F=4, M=1 62–106 115–274 ACE-I/ARB=1 Hypertension=5, CKD=3
Kim et al.21 1 66/F 88.4 115 Diuretic Hypertension
Rocuts et al.22 1 60/F 80 168 ACE-I, diuretic, NSAID Diabetes, hypertension
Demoulin
et al.23
1 50/M 97.2 141.4 ARB Hypertension
Slee et al.24 1 62/F 73 160 ARB, diuretic Hypertension
Total 37 39–85/460 yo: n=26
F=30, M=7
sCr range: 53–150.3
sCr X106: 6/35
sCr range: 76–299
ESRD=4
ACE-I or ARB=20,
diuretics=9, NSAIDs=4
Hypertension=29,
diabetes=5, CKD=8 (defined
as eGFRo60ml/min per
173m2)
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage
renal disease; F, female; NA, not available; NSAID, non-steroidal anti-inflammatory drugs; sCr, serum creatinine concentration. To convert mmol/l to mg/dl, divide by 88.4.
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basophilic rounded concretions, are mainly confined to distal
tubules and collecting duct,3 and are more prominent in the
renal cortex than medulla. The calcifications do not polarize
and have a strong histochemical reaction with the von Kossa
stain, indicating that they are composed of calcium
phosphate (Figure 1b).
Pathogenesis
Both the massive phosphate intake and the consequent
diarrhea-induced hypovolemia appear to be critical factors in
the development of APhN. Phosphate absorption in the small
intestine is loosely controlled and therefore cannot be rapidly
altered following OSP ingestion.4–5 In contrast, proximal
tubular phosphate reabsorption is modulated within minutes
of ingestion, leading to decreased proximal tubular reabsorp-
tion and a rapid increase in delivery to the distal tubule. This
is particularly true following the second dose of OSPS, where
proximal tubular phosphate reabsorption is likely to be fully
inhibited. Although this response is beneficial in most
situations, it appears to be harmful in the setting of profound
volume depletion that often follows OSP-induced diarrhea.
Hypovolemia leads to avid salt and water reabsorption in
both the proximal tubule and descending limb of Henle’s
loop, which is relatively impermeable to calcium and
phosphate.25 The net effect is decreased phosphate reabsorp-
tion in proximal segments of the nephron, leading to a
marked increase in calcium–phosphorus product within the
lumen of the distal tubule. This mechanism is strongly
supported by the observation that calcium phosphate
precipitates in APhN occur predominantly in the distal
tubule and collecting duct.3 Hypovolemia-associated tubular
injury may also precondition the distal tubular epithelium,
leading to the surface expression of hyaluronan and
osteopontin, which in turn creates a ripe environment for
calcium phosphate crystal adherence.26 The magnitude and
duration of the elevation of the distal tubular calcium–pho-
sphorus product are likely to be critical factors in the
development of APhN.
Epidemiological studies
The recognition of APhN as a clinical pathological entity
associated with acute and chronic renal failure has led to
population-based studies that more broadly examine risk
factors and attempt to determine the incidence of this
condition. These studies, which are limited by the absence of
confirmatory renal biopsy and thus unable to diagnose
APhN, have attempted to determine the incidence of AKI or
CKD following OSP use (Table 2).
An observational cohort analysis of 9799 Department of
Defense beneficiaries in the US national capital area, the
largest study to date, was undertaken to examine the
incidence of APhN.27 Patients were identified through an
electronic medical record that has the unique feature of
tracking over the counter medication use, such as OSPS. The
study excluded patients under the age of 50 years (due to the
high incidence of inflammatory bowel disease) and defined
AKI as a X50% increase in serum creatinine from baseline
over 1 year post-colonoscopy. In this study, 114 patients
(1.16%) developed AKI, including 1.29% of the 6432 patients
who received OSPS and 0.92% of the 3367 patients who
received PEG. The PEG group included patients who were
significantly older and had a higher incidence of diabetes
mellitus, HTN, CHF, CKD, diuretic use, and ACE-I or ARB
use (all Po0.05). When multiple logistic regression models
were applied to adjust for covariates and suspected risk
factors, OSPS was found to be the strongest risk factor for the
development of AKI following colonoscopy (odds ratio 2.35;
Po0.001). When AKI was redefined more strictly as doubling
of serum creatinine, an even stronger association between
OSPS and AKI was found (odds ratio 3.52; P¼ 0.03). Most
worrisome was that the number needed to harm was
calculated to be 81 (that is, 1 case of AKI for every 81
OSPS-exposed patients).27
a
b
Figure 1 |Renal biopsy findings in acute phosphate
nephropathy. (a) Case of acute phosphate nephropathy with
abundant intraluminal and intracellular calcifications in distal
tubules. (Hematoxylin and eosin, original magnification  400.)
(b) A positive histochemical reaction with the von Kossa stain
confirms that the tubular concretions are composed of calcium
phosphate (original magnification  400).
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A retrospective case–control study by Brunelli et al.28
evaluated 2237 patients undergoing outpatient colonoscopy.
AKI, defined as a 25% or a 0.5mg/dl increase in serum
creatinine over 6 months post-colonoscopy, was identified in
141 patients (6.3%). Female gender, CHF, and diuretic use
were identified as risk factors for AKI. An association
between OSP and AKI was only identified in patients who
were receiving an ACE-I or ARB. The small sample size and
permissive definition of AKI limit this study, as the mean
increase in creatinine in patients with AKI was only
36.2 mmol/l (0.41mg/dl). Thus, patients with pre-renal
glomerular filtration rate (GFR) changes, likely to occur in
both groups due to bowel prep-induced hypovolemia, would
be identified. A stricter definition of AKI (serum creatinine
increase 488.4 mmol/l (1.0mg/dl)) resulted in a decline in
the number of AKI cases from 116 to 3.28
A retrospective cohort study by Russmann et al.29
included 2352 patients with a baseline GFR 460ml/min
and compared AKI in OSPS versus PEG-exposed patients.
The utility of this study is significantly hampered by the
unusual AKI definition, which required a decline in GFR to
o60ml/min with an interval change of at least 10ml/min or
doubling of baseline serum creatinine. Unbalanced baseline
characteristics were present in the groups, as patients who
received PEG were older and had a higher prevalence of CHF,
HTN, diabetes mellitus, and diuretic and ARB use (P-values
not provided). On univariate analysis, AKI was associated
with age X65 years, HTN, lower baseline GFR, African–
American race, and the use of ACE-I, ARB, or thiazide
diuretics, but was not specifically associated with the use of
OSPS or PEG.29 This study is significantly limited by the bias
toward the inclusion of healthier patients in the OSPS
group. In addition, the unusual definition of AKI further
complicates the results as a 15% decline in GFR from 68 to
58ml/min would meet criteria for AKI but a 33% decline in
GFR from 90 to 60ml/min would not qualify.
Russmann et al.30 subsequently carried out a similar
retrospective analysis on 317 patients with a baseline GFR
o60ml/min in an effort to specifically address the risk of
APhN in patients with moderate CKD. AKI, defined as an
otherwise unexplained increase in serum creatinine
444.2 mmol/l (0.5mg/dl) within 14 days of colonoscopy,
was present in 8 of the 126 patients who used OSPS (6.3%)
versus only 1 of the 191 patients who received PEG (0.5%).
The unadjusted and adjusted relative risk of AKI for OSPS-
exposed patients as compared with PEG users was 12.1 (95%
confidence interval, 1.5–95.8) and 12.6 (95% confidence
interval, 1.5–106.5), respectively. The researchers concluded
that OSPS should not be used in patients with moderate or
severe renal impairment and recommend assessment of renal
function before the use of OSPS in patients who are at risk
for CKD.30
A case–control study examined changes in estimated
GFR (abbreviated MDRD formula) over a 12-month period
in 286 patients who underwent colonoscopy following
OSPS and compared them with an age- and risk factor-
matched cohort of 125 patients who had not undergone
colonoscopy.31 Mean GFR in the study group was 79.33ml/
min per 1.73m2 at baseline, declining to 73.31 and 71.33ml/
min per 1.73m2 at 6 and 12 months post-colonoscopy,
respectively. The 7.6 and 10.1% decline in GFR at 6 and 12
months in the OSPS group was significantly greater than the
Table 2 | Retrospective studies on risk factors for AKI following colonoscopy
Study (reference) Number of patients Renal function inclusion Renal end point
Study results: (OSP
versus PEG or control) Risk factors
Hurst et al.27 OSP: 6432, PEG: 3367 sCr before and within 1 year
of colonoscopy
450% increase in sCr AKI rate: 1.29 vs 0.92%
end point RR: 2.35
(Po0.001)
Old age, CHF, HTN,
ACE-I/ARB, diuretics, DM,
OSPS
Brunelli et al.28 OSP: 296, PEG: 156 sCr (o133mmol/l) before
and within 6 months of
colonoscopy
425% or 444.2mmol/l
increase in sCr
AKI rate: 4.6 vs 6.0%
end point RR: 0.7 (P=NS)
Female gender, CHF,
diuretics
Russmann et al.29 OSP: 2083, PEG: 269 SCr (o133mmol/l) before
and within 6 months of
colonoscopy
GFRo60ml/min and
410ml/min D; or
4100% increase in sCr
AKI rate: 3.8 vs 3.3%
end point RR: 1.14
(P=NS)
Old Age, CKD, HTN,
diuretics, ACE-I/ARB
Khurana et al.31 OSP: 286, Controls:
125
sCr (o133mmol/l) before
and at 6 and 12 months
after colonoscopy
GFR at 6 and 12 months GFR loss (ml/min) 6
months: 6.0 vs 0 12
months: 8.0 vs 1.3
CKD, DM, ACE-I/ARB,
OSPS
Singal et al.32 OSP: 157, PEG: 154 sCr (o133mmol/l) before
and within 1 year of
colonoscopy
425% or 450%
increase in sCr
AKI rate: 5 vs 3% end
point RR: 1.37 (P=NS)
CKD, NSAIDs, OSPS
(did not assess age, HTN,
ACE-I/ARB, diuretics,
gender)
Russmann et al.30 OSP: 126, PEG: 191 Estimated GFR o60ml/min 444.2mmol/l increase
in sCr
AKI rate: 6.3% vs 0.5%
end point RR: 12.6
(CI: 1.5–106.5)
CKD, OSPS
ACE-I, angiotensin-converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin-receptor blocker; CHF, congestive heart failure; Cl, confidence interval; CKD, chronic
kidney disease; DM, diabetes mellitus; GFR, glomerular filtration rate; HTN, hypertension; NSAIDs, non-steroidal anti-inflammatory drugs; OSP, oral sodium phosphate; OSPS
oral sodium phosphate solution; PEG, polyethylene glycol; RR, relative risk; sCr, serum creatinine concentration. To convert mmol/l to mg/dl, divide by 88.4.
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1.7% decline in GFR at 12 months in the control group.
Study significance is limited by the use of a control group
that did not undergo colonoscopy and, more importantly,
inclusion of only OSP-exposed patients who had serum
creatinine determinations at 6 and 12 months post-colono-
scopy (favoring inclusion of sicker patients). As only 10% of
the study participants met these criteria, significant selection
bias is likely.
Two additional studies are worth mentioning. A retro-
spective chart review on 311 patients (98% male) who
received OSPS or PEG found a greater incidence of AKI with
OSPS when AKI was defined as a 25% increase in creatinine,
but not when AKI was defined as a 50% increase in
creatinine.32 A randomized controlled study that enrolled
481 patients and compared OSP tablets (32 tablet Osmoprep)
to PEG reported no cases of AKI.33
Meta-analysis of epidemiological studies
Although case reports and case series provide strong support
for an etiological relationship between OSP and the
development of APhN (Table 1), epidemiological studies
have produced less consistent results (Table 2). Recently,
Brunelli34 undertook a systematic review and meta-analysis
in an attempt to determine the strength of association
between OSP exposure and AKI. Ninety-two potential studies
were evaluated and seven met inclusion criteria of providing
data on renal function outcomes and having a control group.
The seven studies analyzed,27–29,31–33,35 which had varied
baseline kidney function and used different AKI definitions,
did not support an association between OSP and AKI. Using
random effects models, the estimated pooled odds ratios for
OSP versus control were 1.22 (95% confidence interval,
0.77–1.92) and 1.08 (95% confidence interval, 0.71–1.62)
when higher and lower estimates for two studies30,31 were
used. The author concluded that it was not possible to
discern whether an association between OSP and kidney
injury exists. However, a number of limitations of the study
should be considered. Of primary concern is the significant
heterogeneity that exists among the studies as they relate to
choice of bowel preparation, patient populations, baseline
kidney function, AKI definitions, renal outcomes, and
control groups. Second, it is unclear whether the studies
were appropriately weighted, as the most thorough study27
that showed the strong association between OSP and AKI had
twice as many patients as did the other six studies combined.
Third, multiple studies used inappropriate definitions for
AKI29,35 including one that considered follow-up serum
creatinine values as late as 9 years post-OSP exposure.35 In
our opinion, at least one of these studies35 should have been
excluded from the analysis.
Risk factors for APhN
Case reports, case series, and epidemiologic studies (Tables 1
and 2) have facilitated the identification of risk factors for the
development of APhN. These factors in turn provide insight
into the pathogenesis of this condition and may help to
establish safe guidelines for the use of OSP. Some of the risk
factors, including CKD, advanced age, and HTN, can be
broadly viewed as risk factors for AKI in numerous clinical
settings.
Advanced age appears to be an important risk factor for
the development of APhN, as the majority of reported cases
(Table 1) have involved individuals who are 60 years of age or
older (26/37, 70.3%). Advanced age has also been identified
in epidemiological studies as a risk factor for AKI following
the use of OSP27,29 (Table 2). Of note, OSPS exposure is
associated with more severe hyperphosphatemia in the
elderly,36–37 which may relate to both age-related decline in
GFR and increases in intestinal transit time.
Chronic kidney disease is a risk factor for APhN. Before its
withdrawal, ‘clinically significant renal failure’ was listed as a
contraindication to the use of OSPS, although this term was
not specifically defined in terms of GFR. In addition to the
fact that CKD is a general risk factor for all forms of AKI, a
low GFR limits renal phosphate excretion and exposes the
fewer functioning nephrons to a higher concentration of
phosphate. Despite the warning in the product label, 8 of the
37 cases of APhN in Table 1 had a baseline creatinine
X105mmol/l (1.2mg/dl) or estimated GFR o60ml/min per
1.73m2 (CKD stage III or higher). CKD was identified as a risk
factor for AKI following the use of OSP in four of the six studies
in Table 2. Most importantly, the study by Russmann et al.30
suggests that OSP should not be used in patients with stage III
CKD (that is, GFR o60ml/min).
Hypertension. The majority of cases of APhN have
occurred in patients with a history of HTN, including 29 of
the 36 (80.5%) biopsy-proven cases (Table 1). The effect of
HTN may relate to its effect on renal function and the
associated vascular scarring, which can impair physiological
adjustments to hypovolemia. Epidemiological studies sup-
port the association between HTN and AKI following
colonoscopy27,29 (Table 2).
Angiotensin-converting enzyme inhibitors, ARBs, and
diuretics are known to exacerbate the pre-renal state, a
condition that commonly results from OSP-induced diarrhea
and volume depletion. ACE-I and ARB were used in 20 of the
36 cases (55.5%) of biopsy-proven APhN in Table 1, and were
identified as risk factors for OSP-induced AKI in three of
five epidemiological studies in Table 2. An additional, less
critical factor may be that ACE-I and ARB decrease
angiotensin-II-dependent bicarbonate reabsorption in the
proximal tubule, inducing bicarbonaturia38 and promoting
calcium phosphate precipitation in the distal tubule.39 The
rapid reduction in GFR in volume-depleted patients exposed
to ACE-I and ARB also decreases phosphorus disposal,
further promoting intra-luminal calcium phosphate precipi-
tation. Loop or thiazide-type diuretics were administered to 9
of the 36 patients with APhN (25%) in Table 1 and also have
been recognized in epidemiological studies as a risk factor for
AKI following colonoscopy27,29 (Table 2). Diuretics limit the
kidneys’ ability to retain salt and water in the setting of
hypovolemia.
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Female gender. As seen in Table 1, the majority of reported
cases of biopsy-proven APhN have occurred in women (30 of
the 37 cases; 81%). Experimental studies have shown that
female rats are more susceptible to developing nephrocalci-
nosis following exogenous phosphate administration.40 Risk
is likely to be estrogen dependent, as it diminishes in female
rats following oophorectomy and is acquired in male rats
following gonadectomy and estrogen therapy.40 Given that
the majority of women with APhN are post-menopausal, the
critical factor may be that female subjects typically are smaller
than males, as a recent study has shown that body weight is a
critical determinant of the degree of hyperphosphatemia
following the use of OSP.41 These findings raise the issue of
whether OSP dosing should be adjusted for gender and body
weight.
Additional factors which may predispose to the develop-
ment of APhN include diabetes mellitus27,31 and the use of
non-steroidal anti-inflammatory drugs.32 Non-steroidal anti-
inflammatory drug use and diabetes mellitus were only
reported in four (11.1%) and five (13.9%) patients in Table 1,
respectively. As such, firm conclusions about the independent
effect of these risk factors cannot be drawn. Although the
studies in Tables 1 and 2 did not specifically address these
issues, phosphate dose, interval between OSP dosing, and
adequacy of hydration also are undoubtedly critical factors in
determining the risk for the development of APhN.
One might predict that the risk of APhN would increase in
parallel with the number of risk factors. Table 3 lists the
number of risk factors present in each of the 37 patients in
Table 1 with biopsy-proven APhN. All had at least one risk
factor, and 24 of the 36 patients (66 %) had three or more
risk factors. Careful consideration of these risk factors is
likely to lead to more informed, individualized decisions
regarding selection of bowel preparation for patients under-
going colonoscopy.
CONCLUSIONS
Acute phosphate nephropathy is a clinical pathological
entity characterized by acute and subsequent chronic renal
failure following the use of OSP bowel purgatives. Risk
factors for the development of APhN include CKD (i.e., GFR
o60ml/min), older age (i.e., 460 years), HTN, female
gender, treatment with certain antihypertensive agents (ACE-I,
ARB, and diuretics), excess phosphate dosing, inadequate
hydration, and a short interval between OSP administrations
(i.e., o12 h). In December 2008, OSP solution was with-
drawn from the market following the recommendation of the
US Food and Drug Administration. OSP tablets remain
available by prescription. Removal of over the counter OSP,
awareness of the risk factors for APhN, and careful
individualized selection of bowel purgatives should continue
to lead to a marked decline in the incidence of APhN.
DISCLOSURE
GSM is a consultant to Salix Pharmaceuticals.
REFERENCES
1. Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on
tubulointerstitial disease. Clin Chim Acta 2005; 351: 31–47.
2. Desmeules S, Gergeron MJ, Isenring P. Acute phosphate nephropathy
and renal failure. N Engl J Med 2003; 349: 1006–1007.
3. Markowitz GS, Nasr SH, Klein P et al. Renal failure and acute
nephrocalcinosis following oral sodium phosphate bowel cleansing.
Human Pathol 2004; 35: 675–684.
4. Murer H, Hernando N, Forster L et al. Molecular mechanisms in proximal
tubular and small intestinal phosphate reabsorption. Mol Membr Biol
2001; 18: 3–11.
5. Forster IC, Hernando N, Biber J. Proximal tubular handling of phosphate:
a molecular perspective. Kidney Int 2006; 70: 1548–1559.
6. Tenenhouse HS, Gauthier C, Martel J et al. Na+-phosphate cotransport in
mouse distal convoluted tubule cells: evidence for Glvr-1 and Ram-1 gene
expression. J Bone Miner Res 1998; 13: 590–597.
7. Sayer JA, Carr G, Simmons NL. Nephrocalcinosis: molecular insights into
calcium precipitation within the kidney. Clin Sci 2004; 106: 549–561.
8. Vanner SJ, MacDonald PH, Paterson WG et al. A randomized prospective
trial comparing oral sodium phosphate with standard polyethylene
glycol-based lavage solution (Golytely) in the preparation of patients for
colonoscopy. Am J Gastroenterol 1990; 85: 422–427.
9. Cohen SM, Wexner SD, Binderow SR et al. Prospective, randomized,
endoscopic-blinded trial comparing precolonoscopy bowel cleansing
methods. Dis Colon Rectum 1994; 37: 689–696.
10. Golub RW, Kerner BA, Wise WE et al. Colonoscopic bowel preparations—
which one? A blinded, prospective, randomized trial. Dis Colon Rectum
1995; 38: 594–599.
11. Tan JJ, Tjandra JJ. Which is the optimal bowel preparation for
colonoscopy—a meta-analysis. Colorectal Dis 2006; 8: 247–258.
12. Markowitz GS, Stokes MB, Radhakrishnan J et al. Acute phosphate
nephropathy following oral sodium phosphate bowel purgative: an
underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005;
16: 3389–3396.
13. Markowitz GS, Whelan J, D’Agati VD. Renal failure following bowel
cleansing with a sodium phosphate purgative. Nephrol Dial Transplant
2005; 20: 850–851.
14. Gonlusen G, Akgun H, Ertan A et al. Renal failure and nephrocalcinosis
associated with oral sodium phosphate bowel cleansing. Arch Patholo
Lab Med 2006; 130: 101–106.
15. Manley P, Somerfield J, Simpson I et al. Bilateral uraemic optic neuritis
complicating acute nephrocalcinosis. Nephrol Dial Transplant 2006; 21:
2957–2958.
16. Aasebo W, Scott H, Ganss R. Kidney biopsies taken before and after
sodium phosphate bowel cleansing. Nephrol Dial Transplant 2006; 22:
920–922.
17. Beyea A, Block C, Schned A. Acute phosphate nephropathy following oral
sodium phosphate solution to cleanse the bowel for colonoscopy. Am J
Kidn Dis 2007; 50: 151–154.
18. Steinman TI, Samir AE, Cornell LD. Case 27-2008: a 64-year old man with
abdominal pain, nausea, and an elevated level of serum creatinine. N Engl
J Med 2008; 359: 951–960.
19. Connor A, Sykes L, Roberts IS et al. Acute phosphate nephropathy after
sodium phosphate preparations. Br Med J 2008; 337: 47–49.
20. Ori Y, Herman M, Tobar A et al. Acute phosphate nephropathy—an
emerging threat. Am J Med Sci 1008; 336: 309–314.
21. Kim HJ, Lee BH, Kwon SH et al. A case of acute phosphate nephropathy
after sodium phosphate preparation. Korean J Nephrol 2008; 27: 374–377.
Table 3 | Risk factors for acute phosphate nephropathy
Risk factors (n) Number of patients (n)
6 Risk factors 2
5 Risk factors 7
4 Risk factors 8
3 Risk factors 7
2 Risk factors 10
1 Risk factor 3
0 Risk factors 0
Total = 37
Risk factors: age460 years, female gender, GFRo60ml/min, hypertension,
angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, diuretics.
Kidney International (2009) 76, 1027–1034 1033
GS Markowitz and MA Perazella: Acute phosphate nephropathy m in i rev iew
22. Rocuts AK, Waikar SS, Alexander MP et al. Acute phosphate nephropathy.
Kidney Int 2009; 75: 987–991.
23. Demoulin N, Jadoul M, Cosyns JP et al. An easily overlooked iatrogenic
cause of renal failure. Clin Nephrol 2008; 70: 176–177.
24. Slee TM, Vleming LJ, Valentijn RM. Renal failure due to acute phosphate
nephropathy. Netherlands J Med 2008; 66: 438–441.
25. Asplin JR, Mandel NS, Coe FL. Evidence of calcium phosphate
supersaturation in the loop of Henle. Am J Physiol 1996; 270: F604–F613.
26. Verhulst A, Asselman M, De Naeyer S et al. Preconditioning of the distal
tubular epithelium of the human kidney precedes nephrocalcinosis.
Kidney Int 2005; 68: 1643–1647.
27. Hurst FP, Bohen EM, Osgard EM et al. Acute kidney injury associated with
oral sodium phosphate purgative use: an observational retrospective
cohort study. J Am Soc Nephrol 2007; 18: 3192–3198.
28. Brunelli SM, Lewis JD, Gupta M et al. Risk of kidney injury following use of
oral phosphosoda bowel preparations. J Am Soc Nephrol 2007; 18:
3199–3205.
29. Russmann S, Lamerato L, Marfatia A et al. Risk of impaired renal function
after colonoscopy: a cohort study in patients receiving either oral sodium
phosphate or polyethylene glycol. Am J Gastroenterol 2007; 102:
2655–2663.
30. Russmann S, Lamerato L, Motsko SP et al. Risk of further decline in renal
function after the use of oral sodium phosphate or polyethylene glycol in
patients with a preexisting glomerular filtration rate below 60ml/min. Am
J Gastroenterol 2008; 103: 2707–2716.
31. Khurana A, McLean L, Atkinson S et al. The effect of oral sodium
phosphate drug products on renal function in adults undergoing bowel
endoscopy. Arch Intern Med 2008; 168: 593–597.
32. Singal AK, Rosman AS, Post JB et al. The renal safety of bowel
preparations for colonoscopy: a comparative study of oralsodium
phosphate solution and polyethylene glycol. Aliment Pharmacol Ther
2008; 27: 41–47.
33. Johanson JF, Popp JW, Cohen LB et al. A randomized,
multicenter study comparing the safety and efficacy of sodium
phosphate tablets with 2L polyethylene glycol solution plus
bisacodyl tablets for colon cleansing. Am J Gastroenterol 2007; 102:
2238–2246.
34. Brunelli SM. Association between oral sodium phosphate bowel
preparations and kidney injury: a systematic review and meta-analysis.
Am J Kidney Dis 2009; 53: 448–456.
35. Abaskharoun R, Depew W, Vanner S. Changes in renal function following
administration of oral sodium phosphate or polyethylene glycol for colon
cleansing before colonoscopy. Can J Gastroenterol 2007; 21: 227–231.
36. Ainley EJ, Winwood PJ, Begley JP. Measurement of serum electrolytes and
phosphate after sodium phosphate colonoscopy bowel preparation.
Digestive Dis and Sci 2005; 50: 1319–1323.
37. Gumurdulu Y, Serin E, Ozer B et al. Age as a predictor of
hyperphosphatemia after oral phosphosoda administration for colon
preparation. J Gastroenterol Hepatol 2004; 19: 68–72.
38. Haithcock D, Jiao H, Cui XL et al. Renal proximal tubular AT2 receptor:
Signaling and transport. J Am Soc Nephrol 1999; 10: S69–S74.
39. Hesse A, Heimbach D. Causes of phosphate stone formation and the
importance of metaphylaxis by urinary acidification: a review.World J Urol
1999; 17: 308–315.
40. Geary CP, Cousins FB. An oestrogen-linked nephrocalcinosis in rats. Br J
Exp Pathol 1969; 50: 507–515.
41. Ehrenpreis ED. Increased serum phosphate levels and calcium fluxes are
seen in smaller individuals after a single dose of sodium phosphate
bowel cleansing solution: a pharmacologic analysis. Aliment Pharmacol
Ther 2009; E-pub ahead of print.
1034 Kidney International (2009) 76, 1027–1034
min i rev iew GS Markowitz and MA Perazella: Acute phosphate nephropathy
